Mostrando postagens com marcador Inflammatory diseases. Mostrar todas as postagens
Mostrando postagens com marcador Inflammatory diseases. Mostrar todas as postagens

sábado, 8 de novembro de 2014

A cause of age-related inflammation found

 

November 6, 2014

Carnegie Institution

As animals age, their immune systems gradually deteriorate, a process called immunosenescence. It is associated with systemic inflammation and chronic inflammatory disorders, as well as with many cancers. The causes underlying this age-associated inflammation, and how it leads to diseases, are poorly understood. New work sheds light on one protein's involvement in suppressing immune responses in aging fruit flies.


This image shows a comparison of lamin-B in the fat bodies of 10-day-old and 50-day-old fruit flies.

As animals age, their immune systems gradually deteriorate, a process called immunosenescence. It is associated with systemic inflammation and chronic inflammatory disorders, as well as with many cancers. The causes underlying this age-associated inflammation, and how it leads to diseases, are poorly understood. New work in Carnegie's Yixian Zheng's lab sheds light on one protein's involvement in suppressing immune responses in aging fruit flies. It is published in Cell.

Insects have an immune organ called the fat body, which is roughly equivalent to the mammalian fat and liver. It is responsible for many immune functions. Zheng and her team--Carnegie's Haiyang Chen and Xiaobin Zheng--found that the fruit fly fat body experiences a great deal of inflammation in aged flies.

These inflamed fly fat bodies then secrete proteins that lead to a reduction in immune response of the gut. This reduction of the gut immune response causes the gut's stem cells to undergo excessive division and inappropriate differentiation, creating a condition called hyperplasia that shares features with the precancerous polyps found in human guts.

Zheng and her team found that the gradual reduction of a protein called lamin-B in the fat bodies of aging flies is the culprit behind fat body inflammation and the resulting hyperplastic gut, all of which falls under the umbrella of immunosenescence.

Lamin-B is part of the lamin family of proteins, which form the major structural component of the material that lines the inside of a cell's nucleus. Lamins have diverse functions, including suppressing gene expression, and they are found in an array of tissues and organs. In humans, diseases caused by mutations in lamins are called laminopathies and include premature aging.

B-type lamins have long been suspected to play a role in gene suppression by binding to segments of DNA. The team's work revealed that when the fruit fly fat body was depleted of lamin-B, the normal suppression of genes involved in the immune response is reversed, just as it would be in response to bacterial infection or injury, but in this case there is no apparent infection or injury. The un-suppressed immune response initiates the inflammation and resulting gut hyperplasia.

"Our findings have implications for mammals as well as for insects, as immune response genes in mammals also are known to have lamins present on them," Zheng explained. "We think that lamin-B might play an evolutionarily conserved role in suppressing inflammatory genes in immune organs in the absence of infection or injury and our work could provide insight into immunosenescence in humans."


Story Source:

The above story is based on materials provided by Carnegie Institution. Note: Materials may be edited for content and length.


Journal Reference:

  1. Haiyang Chen, Xiaobin Zheng, Yixian Zheng. Age-Associated Loss of Lamin-B Leads to Systemic Inflammation and Gut Hyperplasia. Cell, 2014; 159 (4): 829 DOI: 10.1016/j.cell.2014.10.028

 

domingo, 26 de outubro de 2014

New compounds reduce debilitating inflammation

 

October 24, 2014

Case Western Reserve University

Two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis have been discovered by researchers. The compounds, dubbed OD36 and OD38, appear to curtail inflammation-triggering signals from RIPK2. RIPK2 is an enzyme that activates high-energy molecules to prompt the immune system to respond with inflammation.


Six Case Western Reserve scientists are part of an international team that has discovered two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis. The compounds, dubbed OD36 and OD38, specifically appear to curtail inflammation-triggering signals from RIPK2 (serine/threonine/tyrosine kinase 2). RIPK2 is an enzyme that activates high-energy molecules to prompt the immune system to respond with inflammation. The findings of this research appear in the Journal of Biological Chemistry.

"This is the first published indication that blocking RIPK2 might be efficacious in inflammatory disease," said senior author Derek Abbott, MD, PhD, associate professor of pathology, Case Western Reserve University School of Medicine. "Our data provides a strong rationale for further development and optimization of RIPK2-targeted pharmaceuticals and diagnostics."

In addition to Abbott and his medical school colleagues, the research team included representatives of Oncodesign, a therapeutic molecule biotechnology company in Dijon, France; Janssen Research & Development, a New Jersey-based pharmaceutical company;and Asclepia Outsourcing Solutions, a Belgium-based medicinal chemistry company.

The normal function of RIPK2 is to send warning signals to cells that bacterial infection has occurred, which in turn spurs the body to mobilize white blood cells. The white blood cells identify and encircle pathogens, which cause blood to accumulate in the region. It is this blood build-up that leads to the red and swollen areas characteristic of inflammation. When this process goes awry, the inflammation increases dramatically and tissue destruction ensues. RIPK2 works in conjunction with NOD1 and NOD2 (nucleotide-binding oligomerization domain) proteins in controlling responses by the immune system that lead to this inflammation process.

In this research project, investigators applied state-of-the-art genetic sequencing to learn the unique set of genes driven specifically by NOD2 proteins. They ultimately zeroed in on three specific NOD2-driven inflammation genes (SLC26a, MARCKSL1, and RASGRP1) that guided investigators in finding the most effective compounds.

Oncodesign searched its library of 4,000 compounds that targeted kinases, and after exhaustive study, narrowed the selection down to 13. Then investigators tested the 13 compounds in mouse and human cells and found that two compounds, OD36 and OD38, were most effective in blocking RIPK2.

"Based on the design of OD36 and OD38, we have developed with Oncodesign fifth-generation compounds that are even more effective than the first-generation OD36 and OD38," Abbott said. "Our next step is to seek a larger pharmaceutical company that can move these compounds forward into Phase 1 clinical trials in humans."


Story Source:

The above story is based on materials provided by Case Western Reserve University. The original article was written by Jeannette Spalding. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. T. Tigno-Aranjuez, P. Benderitter, F. Rombouts, F. Deroose, X. Bai, B. Mattioli, F. Cominelli, T. T. Pizarro, J. Hoflack, D. W. Abbott. In Vivo Inhibition of RIPK2 Kinase Alleviates Inflammatory Disease. Journal of Biological Chemistry, 2014; 289 (43): 29651 DOI: 10.1074/jbc.M114.591388